Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Seoul National University

Status and phase: Completed; Phase 3

Conditions: Glomerulonephritis, IGA

Treatments: Drug: Losartan

Study type: Interventional

Funder types: Other

Identifiers

NCT02232776

Losartan_IgA_2014

Details and patient eligibility

About

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

Full description

Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio > 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks.

Enrollment: 37 patients

Sex: All

Ages: 24 months to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age: 2years or older and younger than 18 years
• Biopsy-proven Ig A Nephropathy
• Estimated GFR ≥ 90mL/min/m^2
• Mean urinary protein-creatinine ratio > 0.3 g/g from three first-morning spot urine collections

Exclusion criteria

• hypertension
• under dialysis or organ transplanted
• bilateral renal artery stenosis
• primary hyperaldosteronism
• pregnant

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

37 participants in 1 patient group

Losartan treatement

Experimental group

Description:

All patients had received losartan treatment for 24 weeks.

Treatment:

Drug: Losartan